

December 10, 2018

Subject: Terumo BCT Application in France for the use of the Mirasol® Pathogen Reduction Technology (PRT) System in the treatment of infectious agents in platelets

Dear Valued Customer.

We would like to confirm that Terumo BCT has introduced an application with the authorities in France (Agence Nationale de Sécurité du Medicament et des Produits de Santé, "ANSM") to obtain approval for platelet products treated with the Mirasol® Pathogen Reduction Technology (PRT) System.

This application is currently under review by ANSM. To this end Terumo BCT is in regular contact with ANSM to provide information and to answer questions. ANSM has not yet provided any final decision on the treatment of platelets with the Mirasol PRT system.

The Mirasol PRT system is a CE marked medical device that can be freely sold within the European Union and EEA and other countries that will accept CE marked products. In addition, regulatory approval of the Mirasol PRT system has been obtained in 21 countries and the product has already been sold in 24 countries throughout Europe, the Middle East, Africa, Asia and Latin America.

We encourage open dialogue with our customers and consequently invite you to contact us whenever you have questions about our product portfolio and services. As part of our company Code of Conduct, we do not comment on our competitor's activities.

Thank you for your continued business.

Kind regards,

Pascale Van Hoydonck

Director Regulatory Affairs, EMEA

C1428DZE

Buenos Aires

Terumo BCT Latin America S A

La Pampa 1517-12th Floor